Placeholder Banner

Biotech IP Challenges Around the World: BIO’s Special 301 Submission

February 15, 2012
BIO recently submitted its Special 301 Submission highlighting intellectual property (IP) challenges around the world.  In particular, BIO informed the United States Trade Representative (USTR) of the persistent problems biotech companies face with issues including counterfeiting, large backlogs and patent office inefficiency, differing judicial standards for enforcement, compulsory licensing, inadequate data protection, lack of patentability of biotech inventions, overbearing genetic resources access and benefit regimes, technology transfer issues and a great need for international harmonization of patent standards and procedures.

During the Special 301 Submission process, USTR collects comments from the public which includes a variety of stakeholders such as the Semiconductor, Video Game, Agricultural, PharmaceuticalApparel, Manufacturing and other major exporting U.S. industries.  Associations that focus on IP issues across industries also weigh in including the International Anti-Counterfeiting Coalition, the U.S. Chamber of Commerce, and the International Intellectual Property Alliance USTR will release its final report based on public feedback and its own investigations by embassy officials around the world “on or around April 30, 2012.”